Ovarian Cancer 
Trial Solutions

Enhancing study success with advanced clinical research technologies and expert solutions for Ovarian Cancer trials.

Effective solutions for advancing Ovarian Cancer research

Ovarian cancer often goes undetected until it has reached an advanced stage, at which point it becomes difficult to treat. Researchers are working to develop new and effective therapies for better prognoses, but they need the right tools. Signant SmartSignals solutions can generate reliable evidence while offering a patient-centric experience.

Ovarian

Why Signant Health

  • Generate High-Quality Evidence & Drive New Labeling Claims
  • Simplify the Management of Complex Trial Designs
  • Empower Trials with Early-Phase Tolerability Evidence
  • Increase Patient Comprehension & Ease Burdens for Sites & Patients
  • Gain Richer Insights
  • Generate High-Quality Evidence & Drive New Labeling Claims

    Generate High-Quality Evidence & Drive New Labeling Claims 

    Signant's scientists implement a patient-reported outcomes (PRO) strategy aligned with FDA guidance to meet regulatory and HTA needs. Our solutions help sponsors collect precise measures with optimal frequency to generate informative data for decision-making. Designed with patients in mind, our approach ensures low burden while delivering high-quality data to support regulatory decisions and medication labeling claims.
     

  • Simplify the Management of Complex Trial Designs

    Simplify the Management of Complex Trial Designs 

    Oncology trials present unique challenges in randomization and ensuring medication availability due to complex study designs and treatment-related factors. Signant Health offers a flexible RTSM solution for accurate randomization and a reliable medication supply chain management system that handles variable dosing regimens and treatment interruptions. Partner with Signant Health to confidently navigate oncology trial complexities and ensure successful protocol implementation.
     

  • Empower Trials with Early-Phase Tolerability Evidence

    Empower Trials with Early-Phase Tolerability Evidence 

    Patient-reported outcome measures (PROMs) are underutilized in early-phase trials but are crucial for assessing dose-tolerability and selecting effective doses for later phases. Signant's innovative ePRO solutions simplify the complex task of collecting tolerability data in early-phase studies. By integrating PROMs, we help researchers make informed decisions and optimize oncology drug development. 
     

  • Increase Patient Comprehension & Ease Burdens for Sites & Patients

    Increase Patient Comprehension & Ease Burdens for Sites & Patients

    Our patient-focused engagement solutions simplify clinical trial participation for patients and sites. We can help your patients complete PROs at home, use eConsent for more focused in-clinic visits, and conduct routine follow-ups via telemedicine when appropriate. This approach streamlines the trial process, making it more accessible and accommodating for oncology patients. 
     

  • Gain Richer Insights

    Gain Richer Insights

    Integrate our eCOA with Actigraph sensors and wearables to stream a continuous, real-time view of each patients’ health status directly to the study teams. The objective data on sleep and activity patterns will enable enhanced insights into the post-treatment recovery associated with each treatment cycle.
     

Comprehensive Ovarian Cancer Experience: Phases I-IV

0

STUDIES

0

PATIENTS

0

COUNTRIES

0

SITES

Explore our Ovarian Cancer trial resources
SOLUTION BROCHURE

Ovarian Cancer Trial Solutions Overview


GET INSIGHTS
VIDEO

Ovarian Cancer Trial Solutions



WATCH [2 MIN]
SOLUTION

Oncology Clinical Trial Solutions

 
LEARN MORE

Ready to learn more?

Discover how Signant can support your current or upcoming ovarian cancer trials.